ArticleTherapeutic innovation & regulatory science2017
Culture and Process Change as a Priority for Patient Engagement in Medicines Development.
Article in Therapeutic innovation & regulatory science, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 71 citations in OpenAlex.
- Tensions in patient involvement and engagement in health research and development: a qualitative interview study with key actors.Research involvement and engagement · 2026Article
- Barriers and solutions for healthcare professionals to involve patients as partners in oncology research: Project RISE.Future oncology (London, England) · 2026Article
- Digital Health Technologies: Learnings and Perspectives From a Patient Engagement Stakeholder Expectations Matrix Study.Journal of medical Internet research · 2025Article
- Primer on Plain Language Summaries for Advanced Practice Providers With Published Examples and Practical Applications to Practice.Journal of the advanced practitioner in oncology · 2025Article
- The Role of Patient-Reported Outcomes to Measure Treatment Satisfaction in Drug Development.The patient · 2024Article
- Understanding the patient and supporter journey in cocaine use disorder.Frontiers in psychiatry · 2024Article
- Patient listening on social media for patient-focused drug development: a synthesis of considerations from patients, industry and regulators.Frontiers in medicine · 2024Article
- Co-creation of the Global Patient Experience Data Navigator: a multi-stakeholder initiative to ensure the patient voice is represented in health decision-making.Research involvement and engagement · 2023Article
- Review
- Using Patient Perspectives to Inform Better Clinical Trial Design and Conduct: Current Trends and Future Directions.Pharmaceutical medicine · 2023Review
- Adopting recommendations for implementing patient involvement in cancer research: a funder's approach.Research involvement and engagement · 2023Article
- Patients at the Heart of the Scientific Dialogue: An Industry Perspective.Oncology and therapy · 2023Article
- Supporting patient and public partners in writing lay summaries of scientific evidence in healthcare: a scoping review protocol.BMJ open · 2022Article
- Patient-centred clinical trial design.Nature reviews. Nephrology · 2022Review
- Engaging people with lived experience on advisory councils of a national not-for-profit: an integrated knowledge translation case study of Heart & Stroke Mission Critical Area Councils.Health research policy and systems · 2022Article
- Co-creating with patients an impact framework across the medicine's life cycle: a qualitative study exploring patients' experiences of involvement in and perceptions of impact measures.Research involvement and engagement · 2022Article
- NCI's publication affiliation conundrum: Reframing innovation to incentivize an equitable path for advocate representation.Translational oncology · 2022Article
- Optimising Multi-stakeholder Practices in Patient Engagement: A Gap Analysis to Enable Focused Evolution of Patient Engagement in the Development and Lifecycle Management of Medicines.Therapeutic innovation & regulatory science · 2021Article
- Sustaining Meaningful Patient Engagement Across the Lifecycle of Medicines: A Roadmap for Action.Therapeutic innovation & regulatory science · 2021Article
- Co-creation of practical "how-to guides" for patient engagement in key phases of medicines development-from theory to implementation.Research involvement and engagement · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 9 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Patient Focused Medicines Development (PFMD) is a not-for-profit independent multinational coalition of patients, patient stakeholders, and the pharmaceutical industry with interests across diverse disease areas and conditions. PFMD aims to facilitate an integrated approach to medicines development with all stakeholders involved early in the development process. A key strength of the coalition that differentiates it from other groups that involve patients or patient groups is that PFMD has patient organizations as founding members, ensuring that the patient perspective is the starting point when identifying priorities and developing solutions to meet patients' needs. In addition, PFMD has from inception been formed as an equal collaboration among patient groups, patients, and pharmaceutical industry and has adopted a unique trans-Atlantic setup and scope that reflects its global intent. This parity extends to its governance model, which ensures at least equal or greater share of voice for patient group members. PFMD is actively inviting additional members and aims to expand the collaboration to include stakeholders from other sectors. The establishment of PFMD is particularly timely as patient engagement (PE) has become a priority for many health stakeholders and has led to a surge of mostly disconnected activities to deliver this. Given the current plethora of PE initiatives, an essential first step has been to determine, based on a comprehensive mapping, those strategic areas of most need requiring a focused initial effort from the perspective of all stakeholders. PFMD has identified four priority areas that will need to be addressed to facilitate implementation of PE. These are (1) culture and process change, (2) development of a global meta-framework for PE, (3) information exchange, and (4) training. This article discusses these priority themes and ongoing or planned PFMD activities within each.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.